Cargando…

Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model

The only curative treatment for patients with liver metastases to date is surgery, but few patients are suitable candidates for hepatic resection. The majority of patients will have to rely on other treatment modalities for palliation. Photodynamic therapy (PDT) could be a selective, minimally invas...

Descripción completa

Detalles Bibliográficos
Autores principales: Rovers, J P, Saarnak, A E, Molina, A, Schuitmaker, J J, Sterenborg, H J C M, Terpstra, O T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362893/
https://www.ncbi.nlm.nih.gov/pubmed/10574244
http://dx.doi.org/10.1038/sj.bjc.6690736
_version_ 1782153567620038656
author Rovers, J P
Saarnak, A E
Molina, A
Schuitmaker, J J
Sterenborg, H J C M
Terpstra, O T
author_facet Rovers, J P
Saarnak, A E
Molina, A
Schuitmaker, J J
Sterenborg, H J C M
Terpstra, O T
author_sort Rovers, J P
collection PubMed
description The only curative treatment for patients with liver metastases to date is surgery, but few patients are suitable candidates for hepatic resection. The majority of patients will have to rely on other treatment modalities for palliation. Photodynamic therapy (PDT) could be a selective, minimally invasive treatment for patients with liver metastases. We studied PDT in an implanted colon carcinoma in the liver of Wag/Rij rats, using the photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC). mTHPC tissue kinetics were studied using ex vivo extractions and in vivo fluorescence measurements. Both methods showed that mTHPC kinetics were different for liver and tumour tissue. After initial high levels at 4 h after administration (0.1 and 0.3 mg kg(−1)) mTHPC in liver tissue decreased rapidly in time. In tumour tissue no decrease in photosensitizer levels occurred, with mTHPC remaining high up to 48 h after administration. Both concentration data and fluorescence data showed an increase in tumour to liver ratios of up to 6.3 and 5.0 respectively. Illumination with 652 nm (15 J) resulted in extensive damage to tumour tissue, with necrosis of up to 13 mm in diameter. Damage to normal liver tissue was mild and transient as serum aspartate aminotransferase and alanine aminotransferase levels normalized within a week after PDT treatment. Long-term effects of mTHPC-PDT were studied on day 28 after treatment. Regardless of drug dose and drug–light interval, PDT with mTHPC resulted in complete tumour remission in 27 out of 31 treated animals (87%), with only four animals in which tumour regrowth was observed. Non-responding tumours proved to be significantly larger (P < 0.001) in size before PDT treatment. This study demonstrates that mTHPC is retained in an intrahepatic tumour and that mTHPC-PDT is capable of inducing complete tumour remission of liver tumours. © 1999 Cancer Research Campaign
format Text
id pubmed-2362893
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23628932009-09-10 Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model Rovers, J P Saarnak, A E Molina, A Schuitmaker, J J Sterenborg, H J C M Terpstra, O T Br J Cancer Regular Article The only curative treatment for patients with liver metastases to date is surgery, but few patients are suitable candidates for hepatic resection. The majority of patients will have to rely on other treatment modalities for palliation. Photodynamic therapy (PDT) could be a selective, minimally invasive treatment for patients with liver metastases. We studied PDT in an implanted colon carcinoma in the liver of Wag/Rij rats, using the photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC). mTHPC tissue kinetics were studied using ex vivo extractions and in vivo fluorescence measurements. Both methods showed that mTHPC kinetics were different for liver and tumour tissue. After initial high levels at 4 h after administration (0.1 and 0.3 mg kg(−1)) mTHPC in liver tissue decreased rapidly in time. In tumour tissue no decrease in photosensitizer levels occurred, with mTHPC remaining high up to 48 h after administration. Both concentration data and fluorescence data showed an increase in tumour to liver ratios of up to 6.3 and 5.0 respectively. Illumination with 652 nm (15 J) resulted in extensive damage to tumour tissue, with necrosis of up to 13 mm in diameter. Damage to normal liver tissue was mild and transient as serum aspartate aminotransferase and alanine aminotransferase levels normalized within a week after PDT treatment. Long-term effects of mTHPC-PDT were studied on day 28 after treatment. Regardless of drug dose and drug–light interval, PDT with mTHPC resulted in complete tumour remission in 27 out of 31 treated animals (87%), with only four animals in which tumour regrowth was observed. Non-responding tumours proved to be significantly larger (P < 0.001) in size before PDT treatment. This study demonstrates that mTHPC is retained in an intrahepatic tumour and that mTHPC-PDT is capable of inducing complete tumour remission of liver tumours. © 1999 Cancer Research Campaign Nature Publishing Group 1999-10 /pmc/articles/PMC2362893/ /pubmed/10574244 http://dx.doi.org/10.1038/sj.bjc.6690736 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Rovers, J P
Saarnak, A E
Molina, A
Schuitmaker, J J
Sterenborg, H J C M
Terpstra, O T
Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model
title Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model
title_full Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model
title_fullStr Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model
title_full_unstemmed Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model
title_short Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model
title_sort effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mthpc), in a rat model
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362893/
https://www.ncbi.nlm.nih.gov/pubmed/10574244
http://dx.doi.org/10.1038/sj.bjc.6690736
work_keys_str_mv AT roversjp effectivetreatmentoflivermetastaseswithphotodynamictherapyusingthesecondgenerationphotosensitizermetatetrahydroxyphenylchlorinmthpcinaratmodel
AT saarnakae effectivetreatmentoflivermetastaseswithphotodynamictherapyusingthesecondgenerationphotosensitizermetatetrahydroxyphenylchlorinmthpcinaratmodel
AT molinaa effectivetreatmentoflivermetastaseswithphotodynamictherapyusingthesecondgenerationphotosensitizermetatetrahydroxyphenylchlorinmthpcinaratmodel
AT schuitmakerjj effectivetreatmentoflivermetastaseswithphotodynamictherapyusingthesecondgenerationphotosensitizermetatetrahydroxyphenylchlorinmthpcinaratmodel
AT sterenborghjcm effectivetreatmentoflivermetastaseswithphotodynamictherapyusingthesecondgenerationphotosensitizermetatetrahydroxyphenylchlorinmthpcinaratmodel
AT terpstraot effectivetreatmentoflivermetastaseswithphotodynamictherapyusingthesecondgenerationphotosensitizermetatetrahydroxyphenylchlorinmthpcinaratmodel